# COMMISSIONING STATEMENT ON THE USE OF LIRAGLU意识形态 (SAXENDA®) FOR WEIGHT MANAGEMENT (NICE ES14)

## SUMMARY

NHS Dorset Clinical Commissioning Group does not support the use of liraglutide (Saxenda®) for weight management.

## BACKGROUND

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor antagonist.

Liraglutide (Saxenda®) received a European marketing authorisation in March 2015 and was launched in the UK in January 2017.

Liraglutide as Saxenda® is a different licensed product to liraglutide as Victoza® and the doses of Saxenda® used for weight management are different to that used in managing type 2 diabetes with Victoza®.

## RELEVANT NICE GUIDANCE

NICE ES14 states:

Saxenda® is licensed as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI of:

- 30 kg/m² or more (obese), or
- from 27 kg/m² to less than 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

Treatment should be discontinued after 12 weeks on the 3.0 mg daily dose (recommended maintenance dose) if patients have not lost at least 5% of their initial body weight.

## FORMULARY STATUS

BLACK (not recommended)

## PBR STATUS

In tariff

## COMMISSIONING IMPLICATIONS

There has been no statutory guidance e.g. a NICE Technology Appraisal for this product and the manufacturer has reported that they will only promote the use of liraglutide (Saxenda®) on private prescription, so they anticipate that use on the NHS will be limited. However, there have been requests made from secondary care for GPs to prescribe in primary care which have been declined.

## RELEVANT CLINICAL WORKING GROUP

Diabetes & Endocrinology Working Group of Dorset Medicines Advisory Group (DMAG)
| PATIENT PATHWAY IMPLICATIONS | Saxenda is not specifically mentioned in the NICE guideline on identifying, assessing and managing obesity, however it is another potential pharmacological treatment option for use in line with its marketing authorisation, for adults for whom lifestyle and behavioural approaches have not been effective and for whom the potential benefits of treatment outweigh the risks. |
| SUMMARY OF EVIDENCE TO SUPPORT FORMULARY STATUS | As reported in the European Public Assessment Report (EPAR) for Saxenda®, it is unlikely that any potential weight loss achieved with liraglutide would be sustained after treatment is stopped. In 1 study in adults without type 2 diabetes, after 56 weeks' treatment with liraglutide, participants who switched to placebo gained 2.91% bodyweight over the following 12 weeks compared with 0.69% for those who continued on liraglutide. The summary of product characteristics (SPC) for liraglutide (Saxenda) does not provide further information on how long treatment should be continued for in people who have lost at least 5% of their initial body weight after 12 weeks' treatment. There were high drop-out rates in all of the studies so continuation with treatment may be a problem in practice. There are several special warnings and precautions for use in the SPC for liraglutide (Saxenda), including warnings on pancreatitis, cholelithiasis and cholecystitis, thyroid disease, heart rate, dehydration and hypoglycaemia in people with type 2 diabetes. |
| ASSESSMENT OF COST IMPLICATIONS | Saxenda costs £196.20 for 5 pre-filled disposable injections (30 days' supply) at the maintenance dose of 3.0 mg daily. The manufacturer has reported that they will only promote the use of liraglutide (Saxenda®) on private prescription, so they anticipate that use on the NHS will be limited. Prescribers in Dorset are directed to the guidance on prescribing privately here: https://www.dorsetccg.nhs.uk/Downloads/aboutus/medicines-management/Other%20Guidelines/Private%20Prescribing%20in%20Primary%20Care.pdf |
| REFERENCES | NICE guideline on identifying, assessing and managing obesity (2014) Summary of product characteristics (SPC) for liraglutide (Saxenda®) European Public Assessment Report (EPAR) for Saxenda® |
| DATE | May 2018 |
| REVIEW DATE | April 2020 or before in the light of new information |
| CONTACT FOR THIS POLICY | Diabetes & Endocrinology Working Group of Dorset Medicines Advisory Group (DMAG) via medicine.question@dorsetccg.nhs.uk |